Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Second Primary × dostarlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 18 Endometrial Neoplasms 15 Ovarian Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 7 Squamous Cell Carcinoma of Head and Neck 6 Uterine Cervical Neoplasms 5 Head and Neck Neoplasms 5 Breast Neoplasms 5 Rectal Neoplasms 4 Pancreatic Neoplasms 4 Melanoma 4 Lung Neoplasms 4 Colonic Neoplasms 4 Fallopian Tube Neoplasms 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Osteosarcoma 2 Multiple Myeloma 2 Locally Advanced Rectal Cancer (LARC) 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Turcot syndrome 1

Interventions

Drug Therapy 3 Temozolomide 2 Radiotherapy 2 Radiosurgery 2 Leucovorin 2 Irinotecan 2 Fluorouracil 2 sacubitril and valsartan sodium hydrate drug combination 1 icotinib 1 dostarlimab 1 beta Carotene 1 avelumab 1 alpha-Tocopherol 1 Varenicline 1 Tyrosine Kinase Inhibitors 1 Trastuzumab 1 Tobacco Use Cessation Devices 1 Therapeutics 1 Thalidomide 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Semen Analysis 1 Registries 1 Probiotics 1 Patient Reported Outcome Measures 1 Panitumumab 1 Nicotine Chewing Gum 1 Myofascial Release Therapy 1 Megestrol Acetate 1 Lenalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05855811 2024-07-15

PREDOSTAR

Centre Leon Berard

Phase 2 Recruiting

Neoplasms, Recurrence, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡